Antonio Passaro: I was honored to present in Presidential, the primary results of the global randomized phase 3 study MARIPOSA-2

Antonio Passaro, Medical Oncologist at the European Institute of Oncology, shared on LinkedIn:

“ESMO23 is over and now is the time to gather my thoughts.

I was honored to present in Presidential, the primary results of the global randomized phase 3 study MARIPOSA-2, evaluating amivantamab plus chemotherapy with and without lazertinib, in EGFR-mutant advanced NSCLC after disease progression on osimertinib.

The results met both of the study’s primary endpoints, showing a statistical significant and clinical meaningful improvement of PFS benefit (for both the investigational arms). Of utmost clinical significance both the amivantamab contains combinations led to a benefit in terms of intracranial PFS by BICR compared vs chemotherapy alone.

Overall, this groundbreaking achievement establishes *the new standard of care* in this challenging clinical setting, in favor of the combination of amivantamab plus chemotherapy.

I am grateful to have been part of this study, which saw our site, the Division of Thoracic Oncology of IEO (Directed by Filippo de Marinis) as the first center for accrual worldwide.

My heartfelt thanks extend to everyone who contributed to this remarkable journey: the patients and their families, dedicated caregivers, compassionate nurses, all my colleagues, and staff members involved in data collection: Giulia Sedda, Raffaella Bertolotti, Daniela Brambilla.

A special thanks to all the colleagues J and J Medical Affairs Oncology, The Janssen Pharmaceutical Companies of Johnson and Johnson. Your collective efforts have made a significant impact, shaping the future of cancer research and patient care.

The ESMOdailyReporter article.
The OncLive article.
The La Repubblica article. ”

For the trial click here.
Source: Antonio Passaro/LinkedIn